134 related articles for article (PubMed ID: 37637501)
1. Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial.
Guo J; Bao X; Liu F; Guo J; Wu Y; Xiong F; Lu J
J Hepatocell Carcinoma; 2023; 10():1379-1388. PubMed ID: 37637501
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).
Comito T; Loi M; Franzese C; Clerici E; Franceschini D; Badalamenti M; Teriaca MA; Rimassa L; Pedicini V; Poretti D; Solbiati LA; Torzilli G; Ceriani R; Lleo A; Aghemo A; Santoro A; Scorsetti M
Curr Oncol; 2022 Nov; 29(11):8802-8813. PubMed ID: 36421345
[No Abstract] [Full Text] [Related]
6. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
7. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
Jiang N; Zhong B; Huang J; Li W; Zhang S; Zhu X; Ni C; Shen J
Front Immunol; 2023; 14():1205636. PubMed ID: 37583693
[TBL] [Abstract][Full Text] [Related]
9. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.
Zhu HD; Li X; Ji JS; Huang M; Shao GL; Lu J; Zhao XY; Li HL; Yang ZQ; Tu JF; Zhou JM; Zeng CH; Teng GJ
Eur Radiol; 2022 Nov; 32(11):7335-7343. PubMed ID: 35776182
[TBL] [Abstract][Full Text] [Related]
10. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
11. Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.
Gao Y; Guo J; Bao X; Xiong F; Ma Y; Tan B; Yu L; Zhao Y; Lu J
Oncologist; 2021 Nov; 26(11):e1919-e1930. PubMed ID: 34255901
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
13. Comparison of transarterial bland embolization and drug-eluting beads transarterial chemoembolization for very early and early hepatocellular carcinoma not amenable for surgery or ablation: a single center retrospective data analysis.
Cathomas M; Mueller F; Mertineit N; Baumgartner I; Candinas D; Berzigotti A; Maurer MH; Lachenmayer A
J Gastrointest Oncol; 2023 Oct; 14(5):2167-2177. PubMed ID: 37969817
[TBL] [Abstract][Full Text] [Related]
14. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
[TBL] [Abstract][Full Text] [Related]
16. Interstitial Brachytherapy in Combination With Previous Transarterial Embolization in Patients With Unresectable Hepatocellular Carcinoma.
Schnapauff D; Tegel BR; Powerski MJ; Colletini F; Hamm B; Gebauer B
Anticancer Res; 2019 Mar; 39(3):1329-1336. PubMed ID: 30842165
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Guo W; Chen S; Wu Z; Zhuang W; Yang J
Technol Cancer Res Treat; 2020; 19():1533033820965587. PubMed ID: 33089769
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
